Literature DB >> 27618766

Myoclonus epilepsy in mitochondrial disorders.

Costanza Lamperti1, Massimo Zeviani2.   

Abstract

Mitochondrial disorders is a group of clinical entities associated with abnormalities of the mitochondrial respiratory chain (MRC), which carries out the oxidative phosphorylation (OXPHOS) of ADP into ATP. As the MRC is the result of genetic complementation between two separate genomes, nuclear and mitochondrial, OXPHOS failure can derive from mutations in either nuclear-encoded, or mitochondrial-encoded, genes. Epilepsy is a relatively common feature of mitochondrial disease, especially in early-onset encephalopathies of infants and children. However, the two most common entities associated with epilepsy include MERRF, for Myoclonic Epilepsy with Ragged Red Fibers, and AHS, or Alpers-Huttenlocher syndrome, also known as hepatopathic poliodystrophy. Whilst MERRF is a maternally inherited condition caused by mtDNA mutations, particularly the 8344A>G substitution in the gene encoding mt-tRNALys, AHS is typically caused by recessive mutations in POLG, encoding the catalytic subunit of polymerase gamma, the only mtDNA polymerase in humans. AHS is the most severe, early-onset, invariably fatal syndrome within a disease spectrum, which also include other epileptogenic entities, all due to POLG mutations and including Spino-cerebellar Ataxia and Epilepsy (SCAE). This review reports the main clinical, neuroimaging, biochemical, and molecular features of epilepsy-related mitochondrial syndrome, particularly MERRF and AHS.

Entities:  

Keywords:  Alpers-Huttenlocher syndrome; MELAS; MERRF; hepatopathic poliodystrophy; mitochondrial DNA; mitochondrial respiratory chain; oxidative phosphorylation; progressive myoclonus epilepsies

Mesh:

Year:  2016        PMID: 27618766     DOI: 10.1684/epd.2016.0846

Source DB:  PubMed          Journal:  Epileptic Disord        ISSN: 1294-9361            Impact factor:   1.819


  5 in total

1.  Early-onset genetic epilepsies reaching adult clinics.

Authors:  David Lewis-Smith; Colin A Ellis; Ingo Helbig; Rhys H Thomas
Journal:  Brain       Date:  2020-03-01       Impact factor: 13.501

Review 2.  The best evidence for progressive myoclonic epilepsy: A pathway to precision therapy.

Authors:  Alessandro Orsini; Angelo Valetto; Veronica Bertini; Mariagrazia Esposito; Niccolò Carli; Berge A Minassian; Alice Bonuccelli; Diego Peroni; Roberto Michelucci; Pasquale Striano
Journal:  Seizure       Date:  2019-08-23       Impact factor: 3.184

3.  Antimyoclonic Effect of Levetiracetam and Clonazepam Combined Treatment on Myoclonic Epilepsy with Ragged-Red Fiber Syndrome with m.8344A>G Mutation.

Authors:  Li-Jun Su; Yu-Liang Wang; Tao Han; Shan Qiao; Ke-Jun Zang; Huai-Kuan Wu; Yong-Xin Su; Ling-Ling Liu; Xue-Wu Liu
Journal:  Chin Med J (Engl)       Date:  2018-10-20       Impact factor: 2.628

Review 4.  Mitochondrial DNA Integrity: Role in Health and Disease.

Authors:  Priyanka Sharma; Harini Sampath
Journal:  Cells       Date:  2019-01-29       Impact factor: 6.600

Review 5.  Epilepsy in Mitochondrial Diseases-Current State of Knowledge on Aetiology and Treatment.

Authors:  Dorota Wesół-Kucharska; Dariusz Rokicki; Aleksandra Jezela-Stanek
Journal:  Children (Basel)       Date:  2021-06-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.